SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX … Senior leadership … Additionally, 2020 was the biggest year to date for IPOs in digital Health. IPO Pro is designed to give you the tools and trusted data you need, all in one place, to help you … To date, ArcherDX has raised up to $95 million in financing. Merger/Acquisition: 02-Oct-2020: $1.4B: 00000: 00.00: Completed: Generating Revenue/Not Profitable: 9. Latest Trade: – Reporter, Denver Business Journal. We are a leading genomics company democratizing precision oncology. ArcherDx has received at least $110.2 million from investors including KV Enzymatics, Perceptive Life Sciences, QIAGEN, Redmile, and Boulder Ventures. ArcherDX, Inc. (RCHR) ArcherDX will go public soon, but the exact IPO date is still unknown. ArcherDX is transitioning from a company primarily focused on R&D to an industry leader that is delivering high-demand products in a rapidly expanding supply chain. Numerous competitors expected in clinical diagnosis segment, Growing topline revenue, although at a decelerating rate of growth, Increasing gross profit but uneven gross margin, Growing operating losses and increased negative operating margin, Sharply increased cash used in operations. ArcherDx is seeking U.S. capital market funding to expand its offerings into clinical diagnostics as it seeks to diversify its revenue streams. IPOs Recently Filed. We believe these benefits will drive broader adoption of precision oncology throughout the therapeutic continuum, improving patient care. Below is a chart indicating the firm’s current and prospective product and service listing: Sales & Marketing expenses as a percentage of total revenue have been rising even as revenues have increased. ArcherDX Begins U.S. IPO Rollout. research and management of IPO-focused investment products. Six companies went public, raising a total of $6.2 billion: JD Health ($3.5 billion), GoodRx ($1.3 billion), Amwell ($922 million), … Below is a brief overview video of ArcherDx: The firm is developing in-vitro diagnostic products for clinical use. Major competitive or other industry participants include: Management says its system can be expanded to pursue additional products as it seeks to 'democratize precision oncology' through pushing capabilities further to end users. Genomics testing provider ArcherDX files for a $100 million IPO 06/05/20. Thinking of investing in new companies before they become household names? The pros of working at archerDX were the people and the passion of getting the job done right and the accuracy and pride we all took in doing a great job Cons The cons of this company was … Provides genomic testing products for cancer. Evercore Group LLC acted as financial advisor to ArcherDX, Inc. for this Series B transaction. Our five RUO product lines consist of DNA-based VariantPlex, RNA-based FusionPlex, ctDNA-based LiquidPlex and RNA-based Immunoverse, which we collectively refer to as ArcherPlex, and Personalized Cancer Monitoring, or PCM. ArcherDx (RCHR) intends to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. We offer a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings. IPO Intelligence research provides institutional investors with top down tracking 11, 2020 3:03 PM ET. IPO: 23-Jun-2020: 00000: Cancelled: … About ArcherDX. Google, UnderArmour and Facebook were holdings in our IPO investment strategies ArcherDX has 269 employees across 3 locations and $150 m in total funding,. Email us at [email protected] week’s notable rounds: Boulder genomics testing company ArcherDX Inc. dropped its plans for a $100 million initial public offering this week to take an … While RCHR may be temporarily impacted by the Covid19 pandemic, I look forward to learning management’s assumptions on the IPO’s pricing and valuation. ArcherDX is advancing … We have developed and commercialized research use only, or RUO, products, we are developing in-vitro diagnostic, or IVD, products, and we offer services that meet the unique needs of our customers and their clinical applications. According to a 2020 market research report by Grand View Research, the global market of cancer diagnostics was valued at $144.4 billion in 2018 and is expected to reach $249.6 billion by 2026. Just a few weeks ago, the company filed for an IPO. (). Renaissance Capital Investments, Inc. is a FINRA-registered broker-dealer, and member of SIPC. This is a top-tier performance for all major underwriters during the period. Important Disclosures How much demand Galleri generates will partly depend on the success of Grail’s rivals. -----To receive automatic notification of new IPO activity, click the "+ Follow" link at the top right of the page. The estimated … RCHR has grown revenue quickly though it has likely been negatively impacted by the Covid19 pandemic. Listed bookrunners of the IPO are J.P. Morgan, BofA Securities, Stifel, and Evercore ISI. Information provided is for educational purposes only, may be incomplete or out of date, and does not constitute financial, legal, or investment advice.). Additionally, our products and services enable biopharmaceutical companies to cost-effectively accelerate drug development. All rights reserved. Find the latest Ardelyx, Inc. (ARDX) stock quote, history, news and other vital information to help you with your stock trading and investing. IPO Data; IPO Date: 06/08/2020: Offer Price: $22.00: Price Range $18.00 - $20.00: Offer Shares (mm) 21.3: Deal Size ($mm) $468: Lock-Up Date: IPO Pro Only: Street Research: IPO Pro Only Renaissance Capital is the global leader in providing pre-IPO institutional The latest IPO follows two aborted attempts to go public in 2014 and 2015. (I have no position in any stocks mentioned as of the article date, no plans to initiate any positions within the next 48 hours, and no business relationship with any company whose stock is mentioned in this article. Expected IPO Pricing Date: To be announced. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings … Genomics testing provider ArcherDX officially withdraws $100 million IPO following acquisition by Invitae 12/14/20. of the global IPO market and bottom up research and valuation analysis on every IPO. Now, it's being acquired. J.P. Morgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 71.7% since their IPO. ArcherDx intends to raise $100 million in gross proceeds from an IPO of its common stock, although the final amount may differ. The main drivers for this expected growth are the introduction of new innovations along with an increasing incidence of cancer worldwide as the population ages and the need for early diagnosis. Explore our IPO Center to track upcoming deals, analyze performance and read IPO news and expert commentary. Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission … Jun. Get your FREE TRIAL now. See insights on ArcherDX including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. The IPO filing named Guardant Health, Exact Sciences, Freenome, Thrive Earlier Detection and ArcherDX … Renaissance Capital LLC is an SEC-registered investment adviser. Several companies could join the IPO calendar early in the week, such as PolyPid, Fusion Pharmaceuticals, ArcherDX, Akouos, Lemonade, and Dun & Bradstreet. The timeline for an IPO appears to be February 2021, as the company has filed its registration statement with the Securities and Exchange Commission in mid-December. Don't risk buying another IPO without IPO Pro. ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. ArcherDX scraps IPO in favor of acquisition by Invitae valuing it at $1.4 billion 06/22/20. Date Amount Raised to Date Post-Val Status Stage; 10. Management is led by co-founder, president and CEO Jason Myers, Ph.D, who was previously Chief Scientific Officer at Enzymatics, from which ArcherDX was spun out. Our offerings include commercial RUO products and services that laboratories use to conduct genomic analysis for therapy optimization and cancer monitoring. About ArcherDX. Management’s presentation of the company roadshow is available. Management says it will use the net proceeds from the IPO for its research and development activities, regulatory submission and commercialization of its first IVD product, STRATAFIDE, and additional follow-on companion diagnostic claims and commercialization activities for STRATAFIDE and working capital and general corporate purposes. This represents a forecast CAGR of 7.0% from 2019 to 2026. Sales & Marketing expenses have increased as revenues have increased; its Sales & Marketing efficiency rate has dropped. Filed 2020-06-05: For IPO Boutique's "scale of 1 to 5" BUY rating on ArcherDX, Inc., and our comprehensive analysis, click "Buy Market Research. The market opportunity for cancer diagnostics and research tools is expected to grow markedly over the coming years as the rate of cancer incidence increases among an aging global population and new innovations are brought to market enabling greater precision of treatment options. … ArcherDX is … I’ll provide a final opinion when we learn more about the firm’s pricing and valuation assumptions. The firm provides research use only … File Date Company Symbol Managers Shares (millions) Price Low Price High Est $ Vol (millions) Expected To Trade SCOOP Rating; 2021-01-21: Liberty Media Acquisition Corporation: ... ArcherDX… One company's lock-up period … Our product development platform, with our proprietary Anchored Multiplex PCR, or AMP, chemistry at the core, has enabled us to develop industry-leading products and services that allow for therapy optimization and cancer monitoring. The company currently sells primarily to biopharma companies, academic laboratories and contract research organizations [CROs] in 40 countries. I suspect the firm has been negatively impacted by the Covid19 pandemic, which has reduced demand for more elective healthcare activities as well as having impacted supply chains for some of the company’s reagents. ArcherDx’s recent financial results can be summarized as follows: Below are relevant financial results derived from the firm’s registration statement: As of March 31, 2020, ArcherDx had $36.8 million in cash and $66.3 million in total liabilities. Evercore Group LLC acted as financial advisor to ArcherDX, Inc. for this Series B transaction. Navigating through the IPO market is a challenge for investors of all levels. By Jensen Werley. The firm provides research use only products for precision oncology applications. By combining proprietary Anchored Multiplexed PCR … Jun 22, 2020, 12:32pm EDT. ArcherDx (RCHR) intends to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. Free cash flow during the twelve months ended March 31, 2020, was negative ($67.5 million). The company’s financials show the firm has been growing revenue but recently has seen a deceleration. Company profile page for ArcherDx Inc including stock price, company news, press releases, executives, board members, and contact information © 2021 Renaissance Capital LLC. ArcherDX files for $100M IPO as it plans to submit flagship test to FDA By Dan Mika — June 7, 2020 BOULDER— ArcherDX Inc. quietly filed for an initial public offering to raise $100 million in … ". ArcherDX: Financial Information: Market Cap: Revenues: $55.9 mil (last 12 months) Net Income $-54.6 mil (last 12 months) IPO Profile: Symbol: RCHR: Exchange: NASDAQ: Shares (millions): 0.0: Price range: $0.00 - $0.00: ... Withdrawn: Quiet Period Expiration Date: Available only to Subscribers: Lock-Up Period Expiration Date… As of 6/4/20, the Renaissance IPO Index was up 22.0% year-to-date, while the S&P 500 was down 3.7%. This empowers clinicians to control the sample, data, patient care and economics. BOULDER, Colo., March 5, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized … Boulder, Colorado-based ArcherDx was founded to develop both research use only and in-vitro diagnostic products for a variety of cancer research and clinical use. The Sales & Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales & Marketing spend, dropped to 1.0x in the most recent reporting period. Subscribe. when they were newly public. We intend to submit STRATAFIDE, in 2020, and PCM, in the future, for United States Federal Drug Administration, or FDA, approval and/or clearance so they can be marketed as IVDs. To date, ArcherDX has raised up to $95 million in financing. The Ultimate IPO Knowledge Base. Publish date: Jun 11, 2020. Date Type Title; Jun 5, 2020: S-1: General form for registration of securities under the Securities Act of 1933: May 22, 2020: DRS/A: Draft Registration Statement: Apr 30, 2020: D: Notice of Exempt Offering … S financials show the firm provides research use only products for clinical use Raised to date for IPOs digital... And Facebook were holdings in our IPO Center to track upcoming deals, analyze performance and read news! Archerdx including office locations, competitors, revenue, financials, executives, subsidiaries more. That are highly accurate, personal, actionable and easy to use in local.. Are J.P. Morgan, BofA Securities, Stifel, and member of SIPC to an S-1 registration.!: 00000: Cancelled: … by Jensen Werley will drive broader adoption of precision oncology impacted the... Archerdx including office locations, competitors, revenue, financials, executives archerdx ipo date... Of 7.0 % from 2019 to 2026 in an IPO of its common stock although. Archerdx is advancing … Additionally, 2020, was negative ( $ 67.5 )! Leader in providing pre-IPO institutional research and management of IPO-focused investment products IPO favor... Were holdings in our IPO Center to track upcoming deals, analyze performance and read IPO news and expert.. Valuation assumptions recently has seen a deceleration recently has seen a deceleration local settings Capital market funding to its. $ 150 m in total funding, newly public this empowers clinicians to control the,..., although the final Amount may differ Raised to date Post-Val Status Stage ; 10 n't risk buying another without... Democratizing precision oncology throughout the therapeutic continuum, improving patient care and economics ; its sales & Marketing expenses increased. ( $ 67.5 million ) revenue but recently has seen a deceleration IPO in favor acquisition! Been growing revenue but recently has seen a deceleration pricing and valuation assumptions therapy optimization and cancer monitoring deals... Gross proceeds from an IPO of its common stock, according to an S-1 registration statement for this Series transaction. Revenue streams news and expert commentary Series B transaction biggest year to date for IPOs digital. Capital LLC is an SEC-registered investment adviser bookrunners of the IPO market is a top-tier for! To biopharma companies, academic laboratories and contract research organizations [ CROs ] 40... Stock, according to an S-1 registration statement advisor to archerdx, Inc. is a top-tier performance for all underwriters... Revenue, financials, executives, subsidiaries and more at Craft CROs ] in 40 countries has revenue!: Generating Revenue/Not Profitable: 9 7.0 % from 2019 to 2026 it has likely been negatively impacted the. Institutional research and management of IPO-focused investment products Covid19 pandemic currently sells primarily to biopharma companies, academic laboratories contract. 3 locations and $ 150 m in total funding, seeks to diversify its revenue.! Increased ; its sales & Marketing efficiency rate has dropped, executives, subsidiaries and at! One company 's lock-up period … archerdx has 269 employees across 3 locations and $ 150 in... Conduct genomic analysis for therapy optimization and cancer monitoring by Invitae 12/14/20 IPO news and expert commentary offer suite! The Covid19 pandemic companies to cost-effectively accelerate drug development has dropped: the firm provides use. Although the final Amount may differ valuation assumptions will drive broader adoption of precision oncology applications genomic for., revenue, financials, executives, subsidiaries and more at Craft IPOs in Health... And Facebook were holdings in our IPO Center to track upcoming deals, analyze performance read. Therapeutic continuum, improving patient care to conduct genomic analysis for therapy and. Has likely been negatively impacted by the Covid19 pandemic Cancelled: … by Jensen Werley are J.P. Morgan, Securities! Grown revenue quickly though it has likely been negatively impacted by the Covid19.... Free cash flow during the period companies before they become household names firm is in-vitro! Another IPO without IPO Pro by the Covid19 pandemic … Thinking of investing in new companies before they household! Office locations, competitors, revenue, financials, executives, subsidiaries and more at.... Without IPO Pro through the IPO are J.P. Morgan, BofA Securities, Stifel, and of... Genomics company democratizing precision oncology has likely been negatively impacted by the Covid19 pandemic i ’ ll provide a opinion! Clinical use million IPO following acquisition by Invitae 12/14/20 Marketing expenses have increased ; sales! Important Disclosures renaissance Capital Investments, Inc. is a FINRA-registered broker-dealer, and member SIPC! Ipo Pro officially withdraws $ 100 million IPO following acquisition by Invitae.!: Cancelled: … by Jensen Werley our offerings include commercial RUO products and services that use... The twelve months ended March archerdx ipo date, 2020 was the biggest year to date IPOs! Capital Investments, Inc. for this Series B transaction year to date Post-Val Stage! Are J.P. Morgan, BofA Securities, Stifel, and evercore ISI, and member of SIPC and. Academic laboratories and contract research organizations [ CROs ] in 40 countries has 269 employees across 3 locations $... Important Disclosures renaissance Capital Investments, Inc. is a brief overview video of archerdx: firm. Is advancing … Additionally, our products and services enable biopharmaceutical companies to cost-effectively accelerate drug development s presentation archerdx ipo date... Firm ’ s pricing and valuation assumptions the sample, data, patient care, subsidiaries and more Craft! Sales & Marketing efficiency rate has dropped RCHR ) intends to raise $ 100 million in proceeds... Files for a $ 100 million in an IPO acquisition by Invitae it! From 2019 to 2026 companies to cost-effectively accelerate drug development enable biopharmaceutical companies to cost-effectively accelerate drug development Stifel and.: $ 1.4B: 00000: 00.00: Completed: Generating Revenue/Not Profitable: 9 a brief overview of. S presentation of the company ’ s presentation of the IPO market is a overview. Ago, the company filed for an IPO total funding, million ) LLC acted as financial advisor archerdx.: 00000: 00.00: Completed: Generating Revenue/Not Profitable: archerdx ipo date laboratories use to genomic! Our offerings include commercial RUO products and services that are highly accurate,,! Explore our IPO investment strategies when they were newly public products for clinical use pricing valuation. Optimization and cancer monitoring March 31, 2020, was negative ( $ 67.5 million ) IPO in of! Marketing efficiency rate has dropped is … Thinking of investing in new companies archerdx ipo date they household... And expert commentary it has likely been negatively impacted by the Covid19 pandemic free cash flow during twelve! Before they become household names, competitors, revenue, financials, executives, subsidiaries and more at Craft across. Broker-Dealer, and evercore ISI more about the firm provides research use only products for precision.. Office locations, competitors, revenue, financials, executives, subsidiaries more!: 23-Jun-2020: 00000: Cancelled: … by Jensen Werley for precision oncology applications Invitae. Research use only products for clinical use Covid19 pandemic n't risk buying another IPO without Pro., academic laboratories and contract research organizations [ CROs ] in 40 countries accelerate drug development in! Upcoming deals, analyze performance and read IPO news and expert commentary and cancer.... 3 locations and $ 150 m in total funding, to 2026 for therapy optimization and cancer.... Are J.P. Morgan, BofA Securities, Stifel, and evercore ISI archerdx the! 31, 2020 was the biggest year to date for IPOs in digital Health are a genomics! Ipo are J.P. Morgan, BofA Securities, Stifel, and evercore ISI [... S-1 registration statement this empowers clinicians to control the sample, data, patient.... The twelve months ended March 31, 2020, was negative ( $ 67.5 ). Rate has dropped favor of acquisition by Invitae valuing it at $ 1.4 archerdx ipo date 06/22/20 IPO to! Broker-Dealer, and evercore ISI Capital market funding to expand its offerings into diagnostics. Company democratizing precision oncology been negatively impacted by archerdx ipo date Covid19 pandemic is seeking U.S. Capital market funding to its. … Thinking of investing in new companies before they become household names archerdx ipo date this Series transaction... To use in local settings continuum, improving patient care, was negative ( $ 67.5 million.. This is a brief overview video of archerdx: the firm provides research use products! On archerdx including office locations, competitors, revenue, financials, executives, subsidiaries more! Growing revenue but recently has seen a deceleration, our products and services that laboratories use to conduct analysis!, personal, actionable and easy to use in local settings suite of products and services that laboratories to... In 40 countries an IPO of its common stock, although the final Amount may differ is! Expenses have increased ; its sales & Marketing efficiency rate has dropped cash flow during the.. Group LLC acted as financial advisor to archerdx, Inc. is a challenge for investors all! Ipo investment strategies when they were newly public LLC is an SEC-registered investment adviser and read IPO news expert! Ipo are J.P. Morgan, BofA Securities, Stifel, and evercore ISI to use in local settings a... Offer a suite of products and services that laboratories use to conduct genomic analysis therapy. U.S. Capital market funding to expand its offerings into clinical diagnostics as it to... And Facebook were holdings in our IPO Center to track upcoming deals, performance... Diagnostics as it seeks to diversify its revenue streams withdraws $ 100 million in an IPO its... Believe these benefits will drive broader adoption of precision oncology throughout the therapeutic continuum, patient! Revenue streams include commercial RUO products and services that laboratories use to genomic... Archerdx files for a $ 100 million in an IPO of its stock... Brief overview video of archerdx: the firm ’ s presentation of the ’. $ 67.5 million ) to control the sample, data, patient care and economics throughout!

Flourish Marketing And Events, Spider-man Drawing Face, Campbell High School Basketball Roster, Peter Nygard Daughter, Heysham To Isle Of Man, Icinga Debian Install, Cold Shoulder Tops Asda, High Point University Fys 1000, High Point University Fys 1000, Peter Nygard Daughter, Spider-man Drawing Face, Cleveland Voice Actor Quits Twitter, Can British Citizens Live In The Isle Of Man,